United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the business’s stock in a transaction that occurred on Friday, September 18th. The shares were sold at an average price of $494.79, for a total value of $4,700,505.00. Following the completion of the sale, the chief executive officer owned 324,443 shares of the company’s stock, valued at approximately $160,531,151.97. This trade represents a 2.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

United Therapeutics Price Performance

Shares of UTHR traded down $1.53 during trading hours on Monday, hitting $493.10. The stock had a trading volume of 809,375 shares, compared to its average volume of 514,935. United Therapeutics Corporation has a 1-year low of $409.07 and a 1-year high of $609.35. The firm has a 50 day simple moving average of $515.48 and a 200-day simple moving average of $540.50. The firm has a market capitalization of $21.15 billion, a P/E ratio of 17.64, a price-to-earnings-growth ratio of 2.48 and a beta of 0.56.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, topping the consensus estimate of $6.86 by $0.41. The business had revenue of $783.30 million during the quarter, compared to analysts’ expectations of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The firm’s revenue was down 1.9% on a year-over-year basis. During the same period in the previous year, the business earned $6.41 earnings per share. Equities analysts predict that United Therapeutics Corporation will post 26.21 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in UTHR. BlackRock Inc. bought a new position in shares of United Therapeutics during the second quarter valued at about $2,868,735,000. Janus Henderson Group PLC boosted its holdings in United Therapeutics by 8.9% during the 1st quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company’s stock valued at $514,016,000 after acquiring an additional 70,829 shares during the period. Jupiter Topco LLC purchased a new position in shares of United Therapeutics in the 2nd quarter valued at $450,140,000. Norges Bank purchased a new stake in shares of United Therapeutics during the fourth quarter valued at $293,418,000. Finally, Swedbank AB increased its holdings in United Therapeutics by 0.7% in the first quarter. Swedbank AB now owns 327,122 shares of the biotechnology company’s stock valued at $193,977,000 after buying an additional 2,350 shares in the last quarter. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have recently commented on UTHR shares. Weiss Ratings downgraded United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, August 27th. Bank of America cut their target price on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a report on Friday, July 10th. JPMorgan Chase & Co. lifted their price objective on United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research report on Thursday, July 23rd. Morgan Stanley set a $515.00 price objective on United Therapeutics in a research note on Thursday, August 6th. Finally, Royal Bank Of Canada dropped their price objective on shares of United Therapeutics from $704.00 to $677.00 and set an “outperform” rating on the stock in a report on Thursday, August 6th. Eleven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $646.00.

About United Therapeutics

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening conditions, with a primary emphasis on pulmonary arterial hypertension (PAH). The company’s products are designed to improve pulmonary blood flow and reduce the effects of this progressive disease.

United Therapeutics’ PAH portfolio includes Remodulin (treprostinil) injection, Orenitram (treprostinil) extended-release tablets, and Tyvaso (treprostinil), which is available as an inhalation solution and as the Tyvaso DPI dry-powder inhaler.